Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial Resistance (AMR)

 Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial Resistance (AMR)

Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

Shots:

  • Evotec and GARDP enter into an agreement to develop novel therapies for growing   threat of antimicrobial resistance (AMR)
  •  The focus of the collaboration is to combine GARDP’s clinical expertise with Evotec’s drug discovery platform to develop antibiotics for AMR and establish antibiotic discovery, development platform with portfolio of antibiotic assets
  • Evotec’s anti-infective platform enabling discovery and development of vaccines to treat, prevent serious life-threatening infections arising from Gram-positive and Gram-negative bacteria including MDR organism with a collection of strains producing in-vitro and in-vivo therapies

Click here to read full press release/ article | Ref: Evotec | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post